JP2015510891A - Ｔｏｒキナーゼ阻害剤を用いた癌の治療 - Google Patents

Ｔｏｒキナーゼ阻害剤を用いた癌の治療 Download PDF

Info

Publication number
JP2015510891A
JP2015510891A JP2015500596A JP2015500596A JP2015510891A JP 2015510891 A JP2015510891 A JP 2015510891A JP 2015500596 A JP2015500596 A JP 2015500596A JP 2015500596 A JP2015500596 A JP 2015500596A JP 2015510891 A JP2015510891 A JP 2015510891A
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
pyrazin
tor kinase
kinase inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015500596A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015510891A5 (https=
Inventor
シュ，スイチャン
ヘゲ，クリステン，マエ
レイモン，ヘザー
ロレイン ウォン，リリー
ロレイン ウォン，リリー
Original Assignee
シグナル ファーマシューティカルズ，エルエルシー
シグナル ファーマシューティカルズ，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シグナル ファーマシューティカルズ，エルエルシー, シグナル ファーマシューティカルズ，エルエルシー filed Critical シグナル ファーマシューティカルズ，エルエルシー
Publication of JP2015510891A publication Critical patent/JP2015510891A/ja
Publication of JP2015510891A5 publication Critical patent/JP2015510891A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015500596A 2012-03-15 2013-03-14 Ｔｏｒキナーゼ阻害剤を用いた癌の治療 Pending JP2015510891A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261611361P 2012-03-15 2012-03-15
US61/611,361 2012-03-15
US201261715323P 2012-10-18 2012-10-18
US61/715,323 2012-10-18
PCT/US2013/031206 WO2013138557A1 (en) 2012-03-15 2013-03-14 Treatment of cancer with tor kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019038434A Division JP2019108368A (ja) 2012-03-15 2019-03-04 Ｔｏｒキナーゼ阻害剤を用いた癌の治療

Publications (2)

Publication Number Publication Date
JP2015510891A true JP2015510891A (ja) 2015-04-13
JP2015510891A5 JP2015510891A5 (https=) 2016-03-31

Family

ID=48014336

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015500596A Pending JP2015510891A (ja) 2012-03-15 2013-03-14 Ｔｏｒキナーゼ阻害剤を用いた癌の治療
JP2019038434A Pending JP2019108368A (ja) 2012-03-15 2019-03-04 Ｔｏｒキナーゼ阻害剤を用いた癌の治療
JP2021050188A Pending JP2021102637A (ja) 2012-03-15 2021-03-24 Ｔｏｒキナーゼ阻害剤を用いた癌の治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019038434A Pending JP2019108368A (ja) 2012-03-15 2019-03-04 Ｔｏｒキナーゼ阻害剤を用いた癌の治療
JP2021050188A Pending JP2021102637A (ja) 2012-03-15 2021-03-24 Ｔｏｒキナーゼ阻害剤を用いた癌の治療

Country Status (21)

Country Link
US (1) US20130245026A1 (https=)
EP (1) EP2825170B1 (https=)
JP (3) JP2015510891A (https=)
KR (3) KR102122617B1 (https=)
CN (2) CN108992446A (https=)
AU (1) AU2013203153B2 (https=)
BR (1) BR112014022703A2 (https=)
CA (1) CA2866872A1 (https=)
EA (1) EA028414B1 (https=)
ES (1) ES2677874T3 (https=)
IL (1) IL234602B (https=)
MX (1) MX360878B (https=)
MY (1) MY174022A (https=)
NI (1) NI201400111A (https=)
NZ (1) NZ628416A (https=)
PH (1) PH12014502029B1 (https=)
SG (1) SG11201405707XA (https=)
TW (1) TWI583385B (https=)
UA (1) UA114315C2 (https=)
WO (1) WO2013138557A1 (https=)
ZA (1) ZA201406706B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2866872A1 (en) * 2012-03-15 2013-09-19 Signal Pharmaceuticals, Llc Treatment of cancer with tor kinase inhibitors
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
EP2945636B1 (en) 2013-01-16 2017-06-28 Signal Pharmaceuticals, LLC Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
AU2014254052B2 (en) 2013-04-17 2019-06-06 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
BR112015026292B1 (pt) 2013-04-17 2022-04-12 Signal Pharmaceuticals, Llc Uso de 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-il)piridin-3-il)-3,4-dihidropirazino [2,3-b]pirazin-2(1h)- ona e métodos in vitro
TW201521725A (zh) 2013-04-17 2015-06-16 Signal Pharm Llc 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法
BR112015026297B1 (pt) 2013-04-17 2022-08-23 Signal Pharmaceuticals, Llc Uso de um inibidor da quinase tor e quinazolinona 5-substituída, composição farmacêutica que os compreende, e kit
TW201527300A (zh) 2013-04-17 2015-07-16 Signal Pharm Llc 關於１－乙基－７－（２－甲基－６－（１Ｈ－１，２，４－三唑－３－基）吡啶－３－基）－３，４－二氫吡并［２，３－ｂ］吡－２（１Ｈ）－酮之醫藥調配物、方法、固態型式及使用方法
US9937169B2 (en) 2013-04-17 2018-04-10 Signal Pharmaceuticals, Llc Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
US9782427B2 (en) * 2013-04-17 2017-10-10 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
US20140314673A1 (en) * 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
EP3003313A1 (en) 2013-05-29 2016-04-13 Signal Pharmaceuticals, LLC Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
EP3131552B1 (en) 2014-04-16 2020-07-15 Signal Pharmaceuticals, LLC Methods for treating cancer using tor kinase inhibitor combination therapy
US9512129B2 (en) 2014-04-16 2016-12-06 Signal Pharmaceuticals, Llc Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
EA201790189A1 (ru) 2014-07-14 2017-11-30 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Способы лечения злокачественного новообразования с использованием замещенных пирролопиримидиновых соединений, композиции на их основе
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
EP3641772B1 (en) 2017-06-22 2023-08-02 Celgene Corporation Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010062571A1 (en) * 2008-10-27 2010-06-03 Signal Pharmaceuticals, Llc Mtor kinase inhibitors for oncology indications and diseases associated with the mtor/p13k/akt pathway
US20120028972A1 (en) * 2010-07-30 2012-02-02 Lilly Wong Biomarker assays for detecting or measuring inhibition of tor kinase activity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE543819T1 (de) * 2006-10-19 2012-02-15 Signal Pharm Llc Heteroarylverbindungen, zusammensetzungen daraus und behandlungsverfahren damit
US7968556B2 (en) 2006-10-19 2011-06-28 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and methods of treatment therewith
CA2734828C (en) * 2008-08-20 2018-07-24 J. Silvio Gutkind Chemoprevention of head and neck squamous cell carcinomas
MY177695A (en) 2009-10-26 2020-09-23 Signal Pharm Llc Methods of synthesis and purification of heteroaryl compounds
CA2866872A1 (en) * 2012-03-15 2013-09-19 Signal Pharmaceuticals, Llc Treatment of cancer with tor kinase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010062571A1 (en) * 2008-10-27 2010-06-03 Signal Pharmaceuticals, Llc Mtor kinase inhibitors for oncology indications and diseases associated with the mtor/p13k/akt pathway
US20120028972A1 (en) * 2010-07-30 2012-02-02 Lilly Wong Biomarker assays for detecting or measuring inhibition of tor kinase activity

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AMORNPHIMOLTHAM PANOMWAT: "A RETROINHIBITION APPROACH REVEALS A TUMOR CELL-AUTONOMOUS RESPONSE 以下省略", CANCER RESEARCH, vol. V68 N4, JPN5015004800, 15 February 2008 (2008-02-15), US, pages 1144 - 1153, ISSN: 0003429944 *
LORI BERK: "ANALYSIS OF PHARMACODYNAMIC ACTIVITY OF THE MTOR 以下省略", CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol. V69 N5, JPN5015004803, 10 January 2012 (2012-01-10), DE, pages 1369 - 1377, ISSN: 0003429945 *
OLEKSANDR EKSHYYAN, HEAD & NECK, vol. V32 N12, JPN5015004798, 1 December 2010 (2010-12-01), pages 1619 - 1628, ISSN: 0003429943 *
医学のあゆみ, vol. 222, no. 13, JPN6017024427, 2007, pages 1006 - 1009, ISSN: 0003589822 *
医学のあゆみ, vol. 222, no. 13, JPN6018001822, 2007, pages 1006 - 1009, ISSN: 0003724722 *

Also Published As

Publication number Publication date
EA028414B1 (ru) 2017-11-30
UA114315C2 (uk) 2017-05-25
KR20210071101A (ko) 2021-06-15
CA2866872A1 (en) 2013-09-19
MX2014011077A (es) 2014-10-14
PH12014502029A1 (en) 2014-11-24
JP2021102637A (ja) 2021-07-15
IL234602A0 (en) 2014-11-30
HK1201750A1 (en) 2015-09-11
JP2019108368A (ja) 2019-07-04
ZA201406706B (en) 2016-05-25
KR20200070416A (ko) 2020-06-17
ES2677874T3 (es) 2018-08-07
NI201400111A (es) 2015-01-15
TW201343168A (zh) 2013-11-01
SG11201405707XA (en) 2014-10-30
AU2013203153B2 (en) 2015-09-03
BR112014022703A2 (pt) 2021-05-04
TWI583385B (zh) 2017-05-21
CN104519885A (zh) 2015-04-15
EP2825170A1 (en) 2015-01-21
IL234602B (en) 2020-05-31
CN108992446A (zh) 2018-12-14
MY174022A (en) 2020-03-04
KR20140138927A (ko) 2014-12-04
EA201491699A1 (ru) 2015-02-27
MX360878B (es) 2018-11-21
AU2013203153A1 (en) 2013-10-03
EP2825170B1 (en) 2018-05-09
WO2013138557A1 (en) 2013-09-19
NZ628416A (en) 2016-04-29
PH12014502029B1 (en) 2014-11-24
US20130245026A1 (en) 2013-09-19
KR102122617B1 (ko) 2020-06-12

Similar Documents

Publication Publication Date Title
JP6470822B2 (ja) Ｔｏｒキナーゼ阻害剤を用いた癌の治療
JP6470821B2 (ja) Ｔｏｒキナーゼ阻害剤を用いた癌の治療
JP6470820B2 (ja) Ｔｏｒキナーゼ阻害剤を用いた癌の治療
JP6114554B2 (ja) Ｔｏｒキナーゼ阻害剤に対する感受性についての予測的なバイオマーカーとしてのｌｋｂ１変異の同定
JP2021102637A (ja) Ｔｏｒキナーゼ阻害剤を用いた癌の治療
JP6114317B2 (ja) Ｔｏｒキナーゼ阻害剤の組合せ療法を用いて、非小細胞肺がんを処置する方法
JP2021107461A (ja) Ｔｏｒキナーゼ阻害剤を用いたがんの処置
JP2021050213A (ja) Ｔｏｒキナーゼ阻害剤を用いた癌の治療
JP2016516671A (ja) Ｔｏｒキナーゼ阻害剤を用いたがんの治療
HK1201750B (en) Treatment of cancer with tor kinase inhibitors
AU2015213400A1 (en) Treatment of cancer with TOR kinase inhibitors
HK1202247B (en) Treatment of cancer with tor kinase inhibitors
HK1201755B (en) Treatment of cancer with tor kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161101

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170315

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171106

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20171106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20171106

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20171124

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20180126